FGFR2 and cancer: Here, we demonstrate that similarities between these two cancer types on a molecular level are influenced by KRAS mutation status, as cholangiocarcinoma and KRAS wildtype mPDAC shared genomic (NRG1, FGFR2 fusions and amplification of chr1q) and transcriptomic (upregulation of genes associated with cholangiocytes) features and clustered together independently of KRAS mutant mPDAC when clustered based on a set of KRAS mutation status signature genes.